Two Biotechnology Names Are Hot: Mast Therapeutics, Inc. (MSTX), Novavax, Inc. (NVAX)

Two Biotechnology Names Are Hot: Mast Therapeutics, Inc. (MSTX), Novavax, Inc. (NVAX)

Two Biotechnology Names Are Hot: Mast Therapeutics, Inc. (MSTX), Novavax, Inc. (NVAX)

Mast Therapeutics, Inc. (MSTX) ended last trading session with a change of -2.9 percent. It trades at an average volume of 7.43M shares versus 3.1M shares recorded at the end of last trading session. The share price of $0.11 is at a distance of 57.86 percent from its 52-week low and down -84.44 percent versus its peak. The company has a market cap of $27.63M and currently has 250M shares outstanding. The share price is currently -10.4 percent versus its SMA20, -12.53 percent versus its SMA50, and -54.36 percent versus its SMA200. The stock has a weekly performance of -7.14 percent and is 22.78 percent year-to-date as of the recent close.

On March 6, 2017 Mast Therapeutics, Inc. (MSTX) reported financial results for the fourth quarter and year ended December 31, 2016.

“We are pleased with the progress made with AIR001 during the year and anticipate the closing of the merger with Savara to take place in the second quarter of this year,” stated Brian M. Culley, Chief Executive Officer.  “We believe this merger offers our stockholders a diversified, late-stage product development pipeline with important forthcoming milestones.”

Novavax, Inc. (NVAX) recently recorded -1.37 percent change and currently at $1.44 is 24.14 percent away from its 52-week low and down -83.04 percent versus its peak. It has a past 5-day performance of -2.04 percent and trades at an average volume of 6.4M shares. The stock has a 1-month performance of 9.09 percent and is 14.29 percent year-to-date as of the recent close. There were about 271.92M shares outstanding which made its market cap $391.56M. The share price is currently -1.57 percent versus its SMA20, 3.67 percent versus its SMA50, and -61.07 percent versus its SMA200.

On Feb. 27, 2017 Novavax, Inc., (NVAX) announced its financial results for the fourth quarter and twelve months ended December 31, 2016.

Novavax reported a net loss of $57.1 million, or $0.21 per share, for the fourth quarter of 2016, compared to a net loss of $78.8 million, or $0.29 per share, for the fourth quarter of 2015. For the twelve months ended December 31, 2016, the net loss was $280.0 million, or $1.03 per share, compared to a net loss of $156.9 million, or $0.60 per share, for the same period in 2015.

 

Leave a reply

0 Comments

There are no comments on this post.

Risk Warning: Investing in digital currencies, stocks, shares and other securities, commodities, currencies and other derivative investment products (e.g. contracts for difference (“CFDs”) is speculative and carries a high level of risk. Each investment is unique and involves unique risks.

CFDs and other derivatives are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how an investment works and whether you can afford to take the high risk of losing your money.

Cryptocurrencies can fluctuate widely in prices and are, therefore, not appropriate for all investors. Trading cryptocurrencies is not supervised by any EU regulatory framework. Past performance does not guarantee future results. Any trading history presented is less than 5 years old unless otherwise stated and may not suffice as a basis for investment decisions. Your capital is at risk.

When trading in stocks your capital is at risk.

Past performance is not an indication of future results. Trading history presented is less than 5 years old unless otherwise stated and may not suffice as a basis for investment decisions. Prices may go down as well as up, prices can fluctuate widely, you may be exposed to currency exchange rate fluctuations and you may lose all of or more than the amount you invest. Investing is not suitable for everyone; ensure that you have fully understood the risks and legalities involved. If you are unsure, seek independent financial, legal, tax and/or accounting advice. This website does not provide investment, financial, legal, tax or accounting advice. Some links are affiliate links. For more information please read our full risk warning and disclaimer.